Literature DB >> 11588459

Autoantibodies to lipids in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome.

L Maneta-Peyret1, E Kitsiouli, M Lekka, G Nakos, C Cassagne.   

Abstract

OBJECTIVE: To investigate the presence of autoantibodies to lipids in the bronchoalveolar lavage (BAL) fluid from adult patients with acute respiratory distress syndrome (ARDS).
DESIGN: Analysis of immunoglobulin G (IgG) in BAL fluid by electrophoresis followed by immunoblotting and characterization of immunoglobulins as antilipid autoantibodies.
SETTING: Intensive care unit of a university hospital and two research university laboratories.
SUBJECTS: Twenty-seven mechanically ventilated patients in total, including nine patients with ARDS and two control groups.
INTERVENTIONS: Patients were ventilated with a mechanical ventilation mode. Six aliquots of 20-mL sterile normal saline at 37 degrees C were infused through the working channel of the bronchoscope. MEASUREMENTS: Total protein, detection of IgG by electrophoresis followed by immunoblotting, and characterization of IgG by enzyme-linked immunosorbent assay using different lipids as target antigens. MAIN
RESULTS: Antiphospholipid autoantibodies are present in BAL fluid of ARDS patients. Among the phospholipids tested, phosphatidic acid and phosphatidylserine gave the most significant activity. The IgG fraction, purified from BAL fluids by affinity chromatography, gave the same pattern of binding as that of the BAL fluid.
CONCLUSION: The presence of antiphospholipid autoantibodies in BAL fluid suggests involvement of autoimmune mechanisms in the pathogenesis of ARDS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588459     DOI: 10.1097/00003246-200110000-00017

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Alveolar and serum antiphospholipid antibodies in acute respiratory distress syndrome associated with catastrophic antiphospholipid syndrome.

Authors:  F J Wiedermann
Journal:  Ann Rheum Dis       Date:  2006-03       Impact factor: 19.103

2.  Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome.

Authors:  G Nakos; E Tziakou; L Maneta-Peyret; C Nassis; M E Lekka
Journal:  Intensive Care Med       Date:  2005-07-26       Impact factor: 17.440

3.  Identification of immunoglobulins that recognize 3-nitrotyrosine in patients with acute lung injury after major trauma.

Authors:  Leonor Thomson; Jason Christie; Caryn Vadseth; Paul N Lanken; Xiaoming Fu; Stanley L Hazen; Harry Ischiropoulos
Journal:  Am J Respir Cell Mol Biol       Date:  2006-10-05       Impact factor: 6.914

4.  The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients.

Authors:  S Bucciarelli; G Espinosa; R A Asherson; R Cervera; G Claver; J A Gómez-Puerta; M Ramos-Casals; M Ingelmo
Journal:  Ann Rheum Dis       Date:  2005-05-26       Impact factor: 19.103

5.  Catastrophic antiphospholipid syndrome presented with severe hypertension, adult respiratory distress syndrome and unilateral adrenal haemorrhagic infarction.

Authors:  Ioannis Starakis; Elias Mazokopakis; Dimitris Siagris; Stamatis Liossis; Chrysoula Karatza; Andrew Antonopoulos
Journal:  Rheumatol Int       Date:  2007-04-14       Impact factor: 3.580

Review 6.  Antiphospholipid antibodies in critically ill patients.

Authors:  Juliana Vassalo; Nelson Spector; Ernesto de Meis; Márcio Soares; Jorge Ibrain Figueira Salluh
Journal:  Rev Bras Ter Intensiva       Date:  2014 Apr-Jun

Review 7.  The pulmonary pathology of COVID-19.

Authors:  Hans Bösmüller; Matthias Matter; Falko Fend; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2021-02-19       Impact factor: 4.064

8.  Does activation of the FcgammaRIIa play a role in the pathogenesis of the acute lung injury/acute respiratory distress syndrome?

Authors:  Rafal Fudala; Agnieszka Krupa; Dorota Stankowska; Timothy C Allen; Anna K Kurdowska
Journal:  Clin Sci (Lond)       Date:  2010-01-26       Impact factor: 6.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.